Over the course of a year, The CLL Society Bloodlinewill teach the BASICS needed to understand CLL. It will provide news, help with acronyms and new vocabulary words, and offer simple fun quizzes. The cycle restarts and it is updated annually.
MONTHLY QUIZ: CLL is classified as:
- A lymphoma, as it arises from lymphocytes.
- A leukemia, because the cancer cells are found in the blood stream.
- Neither, as it is a hybrid disease that is classified by itself.
- Both, as it arises from lymphocytes and is a blood cancer.
Answer: The correct answer is 4 or both. All cancers that arise from lymphocytes, a type of our white blood cells, are called lymphomas. As CLL is a cancer of the lymphocytes, specifically the B lymphocytes, it is included in the broad category of Non-Hodgkin’s Lymphomas (NHL). That’s good because we may qualify for NHL clinical trials. It is also a leukemia as the cancerous lymphocytes appears in the blood in most patients. SLL (small lymphocytic lymphoma) is a less common form of the exact same disease where the cancer cells are not found in excess in the blood stream.
NEWS:
Join CLL Society for our webinar Shared Decision-Making in CLL: Partnering With Your Doctor to Choose the Right Path with speakers Dr. John Burke, and patient advocates Christina Fisher and Stephen Feldman.
If you missed the March virtual event, you can catch the replay here: Ask Me Anything: Featuring Dr. Ryan Jacobs and Doreen Zetterlund.
CLL Society’s Ambassador Program connects you with a fellow patient who has received the treatment you’re considering so you can ask questions and gain insights to feel more confident in your decisions.
THE BASICS: Test Before TreatTM
It is critical to do prognostic and predictive tests before starting each and every treatment. These tests predict the likelihood that our CLL / SLL will respond to different therapies. One critical test is FISH (fluorescent in situ hybridization) that looks for chromosome abnormalities in the cells’ nuclei. For example, finding deletion 17p (del17p) means all chemoimmunotherapy (CIT) won’t work and some targeted therapies may work better than others. Another test examines the maturity of our cancer cells by looking at IgHV (aka IgVH) mutation. Patients with more mature or mutated IgHV tend to have a slower growing or indolent form of CLL. TP53 should also be assessed by Next Generation Sequencing (NGS) as its mutation also predicts for poor response to CIT and more aggressive disease. Check out our Test Before Treat™ pages on the website.
WORD/ACRONYM OF THE MONTH: Immunocompromised or Immunosuppressed
All CLL patients regardless of their treatment status are immunocompromised to some extent that depends on disease stage and treatment history. Immunocompromised is a catchall term for different weakened immune defenses. 85% of CLL patients make lower than normal amounts of antibodies or immunoglobulins such as IGG. Immunoglobulin replacement therapy (IGRT) that can be given either by IV or self-administered subcutaneously at home may help. T cell function or cellular immunity and the more primitive innate immune system may also be impaired. This increases the risk for all infections (not only COVID-19), and for second cancers. Infection precautions and age and gender appropriate cancer screenings are critical, especially as CLL patients are living longer with newer better treatments.
CLL Society is invested in your long life. Please invest in the long life of CLL Society.
